Hepatitis C Is Now Curable: Why One Blood Test Matters

Key Takeaways:

• The US Preventive Services Task Force recommends screening for hepatitis C in all adults aged 18 to 79 without known liver disease, concluding with moderate certainty that screening has substantial net benefit (a grade B recommendation, 2020).
• Modern direct-acting antiviral pills cure hepatitis C in more than 95 percent of patients in most groups studied: a once-daily 12-week regimen achieved a 99 percent sustained virologic response across genotypes 1, 2, 4, 5, and 6, and an 8-week regimen cured 99.1 percent of genotype 1 patients without cirrhosis.
• Cure changes outcomes: among patients with advanced liver fibrosis or cirrhosis, ten-year all-cause mortality was 8.9 percent in those who cleared the virus versus 26.0 percent in those who did not.

Hepatitis C is a quiet infection with a loud ending. The virus spreads through blood, and in most people who catch it, the immune system fails to clear it, so the infection settles into the liver for years or decades. It rarely announces itself. Instead, the virus drives a slow, low-grade inflammation in liver cells, and each round of injury and repair lays down a little more scar tissue, a process called fibrosis. Over enough time, that scarring can progress to cirrhosis, liver failure, and liver cancer, often in someone who felt entirely well until late in the course. The scale is easy to underestimate. Hepatitis C is the most common chronic bloodborne infection in the United States, it is associated with more deaths than the top 60 other reportable infectious diseases combined, and new acute infections rose about 3.8-fold in the decade before the 2020 screening recommendation, driven largely by injection drug use. What changed everything is that a hepatitis C cure is now routine. Unlike hepatitis B or HIV, hepatitis C never converts its genome into DNA or parks it in the cell nucleus, so it has no dormant reservoir; it survives only by constantly copying itself. Direct-acting antivirals exploit that weakness by blocking the specific viral proteins the virus needs to replicate, including its NS3/4A protease, its NS5A protein, and its NS5B polymerase. Shut down replication long enough and the virus simply runs out, which is why a cure here is a cure in the full sense.

The trial results are about as clean as medicine gets. In a double-blind, placebo-controlled phase 3 trial, 624 patients with hepatitis C genotypes 1, 2, 4, 5, or 6, including people with compensated cirrhosis and people who had failed earlier treatment, took a single combination tablet of sofosbuvir and velpatasvir once daily for 12 weeks. Ninety-nine percent achieved a sustained virologic response, meaning no detectable virus 12 weeks after finishing therapy, which is the accepted definition of cure; none of the 116 patients on placebo cleared the virus. Another pair of phase 3 trials involving 1,208 patients found that eight weeks of glecaprevir and pibrentasvir cured 99.1 percent of genotype 1 patients without cirrhosis, and 12 weeks cured 95 percent of those with the harder-to-treat genotype 3. A systematic review of 42 trials of oral antiviral combinations confirmed that six regimens reached cure rates above 95 percent in genotype 1 infection without cirrhosis, with serious side effects and treatment discontinuation below 10 percent. The review also marks the limit: patients whose liver had already decompensated were cured less often, at 78 to 87 percent. That is the strongest argument for finding the infection early. Because treatment is short, well tolerated, and highly effective, the US Preventive Services Task Force in 2020 recommended screening all adults aged 18 to 79 at least once, not just those with known risk factors.

What does a hepatitis C cure mean for your health?

It means the damage can stop accumulating, and the long-term data suggest it translates into longer lives. In an international study of 530 patients with advanced fibrosis or cirrhosis who were treated in the older interferon era and followed for a median of 8.4 years, those who cleared the virus had a ten-year all-cause mortality of 8.9 percent, compared with 26.0 percent in those who did not, and a cure was associated with roughly a 74 percent lower risk of death. That study predates today’s pills, but it shows what eliminating the virus does, and modern regimens now achieve that elimination in nearly everyone who completes treatment. Screening itself is simple: an antibody blood test, followed by a test for the virus’s genetic material if the antibody is positive, since a positive antibody can reflect an old infection that has already cleared. A few practical points matter. Cure does not create reliable protective immunity, so anyone with ongoing exposure, such as shared injection equipment, can be reinfected and may need repeat testing. People who already have cirrhosis when they are cured still need ongoing liver monitoring, because the scar tissue that formed before treatment does not vanish overnight. And because so many infections are silent, the most important step is the least dramatic one: if you are an adult who has never been tested, ask for the one-time blood test at your next visit.

References:

1. Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., et al. (2020). Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA, 323(10), 970-975.
2. Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P. J., Gruener, N., et al. (2015). Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. The New England Journal of Medicine, 373(27), 2599-2607.
3. Zeuzem, S., Foster, G. R., Wang, S., Asatryan, A., Gane, E., Feld, J. J., et al. (2018). Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. The New England Journal of Medicine, 378(4), 354-369.
4. Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017). Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review. Annals of Internal Medicine, 166(9), 637-648.
5. van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J. F., Lammert, F., et al. (2012). Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 308(24), 2584-2593.